Patent Litigation Involving Cancer Immunotherapy
This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Background
A biopharmaceutical company had exclusively licensed a patent related to CAR-T therapy, a novel type of cancer immunotherapy that modifies a patient’s T cells to target and kill cancer more effectively. Its primary competitor had previously attempted to license and invalidate the patent, but failed at both. Despite being aware of potential infringement claims against its therapy, the competitor prioritized being first to market for its lead indication, attempting to lock in a sizeable portion of what was viewed to be a blockbuster marketplace. Upon its competitor achieving FDA approval, the company filed patent infringement claims against its competitor and its therapy.
Our Analysis
Intensity was called upon to evaluate the damages related to the alleged infringement. For this project, Intensity conducted economic analysis and provided trial testimony to determine reasonable royalties. This included an assessment of the economic contribution of the patented technology to the allegedly infringing product, availability of potential non-infringing alternatives, stage of development of licensed technology, competitive relationship between the two parties, financial harms and benefits from use of the patented technology by the alleged infringer, and market analysis of related license agreements. As part of its work, Intensity evaluated all fifteen of the Georgia-Pacific factors.
Intensity submitted an expert report and provided expert testimony at deposition and trial. After an eight-day trial, the jury returned a verdict in favor of Intensity’s client with a damages award that precisely matched the trial testimony.
Economic issues included: Apportionment; Discounted Cash Flow; Licensing; Reasonable Royalty; Valuation.
Latest Insights
News | December 4, 2025
Secretariat Expert Valuation Helps Secure Historic $5.89 Billion Citgo Sale Order
In a complex federal court case in Delaware with far-reaching geopolitical significance, Managing Director Gary Kleinrichert’s expert financial valuation helped secure approval of a landmark $5.89 billion Citgo sale opinion that could help resolve billions of dollars in unpaid judgments against Venezuela and certain of its instrumentalities.
News | December 4, 2025
Secretariat Named Arbitration Expert Firm of the Year at 2025 Lexology Index Awards
Secretariat is delighted to announce that we were named as the Arbitration Expert Firm of the Year at the prestigious 2025 Lexology Index Awards Ceremony, held at Merchant Taylors’ Hall in London. We are honored to be recognized by clients and peers as the foremost experts leading and shaping the global arbitration community.
See All Insights
Talk to Our Insightful Experts